Edwards Lifesciences (NYSE:EW) Price Target Increased to $105.00 by Analysts at Mizuho

Edwards Lifesciences (NYSE:EW) had its price objective raised by Mizuho from $95.00 to $105.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Mizuho’s target price points to a potential upside of 16.24% from the stock’s previous close.

A number of other equities analysts have also commented on EW. Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target on the stock in a research report on Friday, February 2nd. Evercore ISI boosted their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Citigroup boosted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, Morgan Stanley boosted their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.33.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $90.33 on Thursday. The company has a market cap of $54.37 billion, a PE ratio of 39.27, a P/E/G ratio of 4.53 and a beta of 1.05. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $90.01 and a 200 day simple moving average of $77.68.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences will post 2.76 EPS for the current year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, Director Heisz Leslie Stone sold 7,056 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the completion of the sale, the director now directly owns 26,980 shares of the company’s stock, valued at $2,332,421. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last three months. 1.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of the company. Castleview Partners LLC purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. DSM Capital Partners LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at approximately $28,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences in the 4th quarter worth approximately $31,000. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $34,000. Finally, Riverview Trust Co purchased a new position in Edwards Lifesciences in the first quarter valued at $34,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.